{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:07:18Z","timestamp":1791493638582,"version":"4.3.4"},"reference-count":143,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"KWF Kankerbestrijding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    <jats:italic>In situ<\/jats:italic>\n                    tumor ablation techniques, like radiotherapy, cryo- and heat-based thermal ablation are successfully applied in oncology for local destruction of tumor masses. Although diverse in technology and mechanism of inducing cell death, ablative techniques share one key feature: they generate tumor debris which remains\n                    <jats:italic>in situ<\/jats:italic>\n                    . This tumor debris functions as an unbiased source of tumor antigens available to the immune system and has led to the concept of\n                    <jats:italic>in situ<\/jats:italic>\n                    cancer vaccination. Most studies, however, report generally modest tumor-directed immune responses following local tumor ablation as stand-alone treatment. Tumors have evolved mechanisms to create an immunosuppressive tumor microenvironment (TME), parts of which may admix with the antigen depot. Provision of immune stimuli, as well as approaches that counteract the immunosuppressive TME, have shown to be key to boost ablation-induced anti-tumor immunity. Recent advances in protein engineering have yielded novel multifunctional antibody formats. These multifunctional antibodies can provide a combination of distinct effector functions or allow for delivery of immunomodulators specifically to the relevant locations, thereby mitigating potential toxic side effects. This review provides an update on immune activation strategies that have been tested to act in concert with tumor debris to achieve\n                    <jats:italic>in situ<\/jats:italic>\n                    cancer vaccination. We further provide a rationale for multifunctional antibody formats to be applied together with\n                    <jats:italic>in situ<\/jats:italic>\n                    ablation to boost anti-tumor immunity for local and systemic tumor control.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2021.617365","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T02:58:33Z","timestamp":1618369113000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":45,"title":["Immune Modulation Plus Tumor Ablation: Adjuvants and Antibodies to Prime and Boost Anti-Tumor Immunity In Situ"],"prefix":"10.3389","volume":"12","author":[{"given":"Renske J. E.","family":"van den Bijgaart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Schuurmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurgen J.","family":"F\u00fctterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenneke A. M.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gosse J.","family":"Adema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02874","article-title":"Huis In \u2018t Veld LGM, Raaijmakers TK, Adema GJ. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines","volume":"9","author":"Ho","year":"2018","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-0206","article-title":"Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine","volume":"66","author":"den Brok","year":"2006","journal-title":"Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(17)61690-2","article-title":"Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations","volume":"104","author":"Soanes","year":"1970","journal-title":"J Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70082-8","article-title":"Systemic effects of local radiotherapy","volume":"10","author":"Formenti","year":"2009","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1520-4","article-title":"Cryoimmunotherapy with local co-administration of ex vivo generated dendritic cells and CpG-ODN immune adjuvant, elicits a specific antitumor immunity","volume":"63","author":"Alteber","year":"2014","journal-title":"Cancer Immunol Immunother CII"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.11.080","article-title":"Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction","volume":"30","author":"den Brok","year":"2012","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1891-9","article-title":"Thermal and mechanical high-intensity focused ultrasound: perspectives on tumor ablation, immune effects and combination strategies","volume":"66","author":"van den Bijgaart","year":"2017","journal-title":"Cancer Immunol Immunother CII"},{"key":"B8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"mAbs"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3007","article-title":"Strategies to improve radiotherapy with targeted drugs","volume":"11","author":"Begg","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2019.07.021","article-title":"The transformation of radiation oncology using real-time magnetic resonance guidance: A review","volume":"122","author":"Hall","year":"2019","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2741\/4487","article-title":"Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation","volume":"22","author":"Keisari","year":"2017","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.3520","article-title":"In vivo MR guided boiling histotripsy in a mouse tumor model evaluated by MRI and histopathology","volume":"29","author":"Hoogenboom","year":"2016","journal-title":"NMR BioMed"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2015.1007538","article-title":"Histotripsy methods in mechanical disintegration of tissue: towards clinical applications","volume":"31","author":"Khokhlova","year":"2015","journal-title":"Int J Hyperthermia"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ultsonch.2017.02.035","article-title":"Impact of MR-guided boiling histotripsy in distinct murine tumor models","volume":"38","author":"Hoogenboom","year":"2017","journal-title":"Ultrason Sonochem"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500541","article-title":"Low-Intensity Focused Ultrasound Induces Reversal of Tumor-Induced T Cell Tolerance and Prevents Immune Escape","volume":"196","author":"Bandyopadhyay","year":"2016","journal-title":"J Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2015.02.006","article-title":"Mechanical high-intensity focused ultrasound destruction of soft tissue: working mechanisms and physiologic effects","volume":"41","author":"Hoogenboom","year":"2015","journal-title":"Ultrasound Med Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1089\/end.2007.9915","article-title":"Histotripsy of rabbit renal tissue in vivo: temporal histologic trends","volume":"21","author":"Hall","year":"2007","journal-title":"J Endourol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2018.1539253","article-title":"Engineering T cell response to cancer antigens by choice of focal therapeutic conditions","volume":"36","author":"Shao","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0013","article-title":"Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy","volume":"4","author":"Page","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1586\/14760584.4.5.699","article-title":"Dendritic cells: tools and targets for antitumor vaccination","volume":"4","author":"den Brok","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-2154","article-title":"Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells","volume":"71","author":"Nierkens","year":"2011","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01014","article-title":"Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity","volume":"10","author":"Noubade","year":"2019","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-07-6023","article-title":"In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy","volume":"68","author":"Nierkens","year":"2008","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e8368","DOI":"10.1371\/journal.pone.0008368","article-title":"Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice","volume":"4","author":"Nierkens","year":"2009","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-0501","article-title":"Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2\/neu immunity","volume":"74","author":"Veenstra","year":"2014","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-018-0184-y","article-title":"TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis","volume":"16","author":"Xu","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-3026","article-title":"Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies","volume":"22","author":"Monjazeb","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.7150\/thno.25613","article-title":"Distinct immune signatures in directly treated and distant tumors result from TLR adjuvants and focal ablation","volume":"8","author":"Chavez","year":"2018","journal-title":"Theranostics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000194","article-title":"Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy","volume":"204","author":"Blair","year":"2020","journal-title":"J Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13543","article-title":"Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model","volume":"109","author":"Yoshida","year":"2018","journal-title":"Cancer Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210913","article-title":"TLR7 and TLR8 as targets in cancer therapy","volume":"27","author":"Schon","year":"2008","journal-title":"Oncogene"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e1802228","DOI":"10.1002\/adma.201802228","article-title":"Nanoparticle-Enhanced Radiotherapy to Trigger Robust Cancer Immunotherapy","volume":"31","author":"Chen","year":"2019","journal-title":"Adv Mater"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-12-0984","article-title":"Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer","volume":"18","author":"Dewan","year":"2012","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.7928","article-title":"Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy","volume":"7","author":"Dovedi","year":"2016","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700777","article-title":"Imiquimod enhances the systemic immunity attained by local cryosurgery destruction of melanoma lesions","volume":"127","author":"Redondo","year":"2007","journal-title":"J Invest Dermatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"24477","DOI":"10.1038\/srep24477","article-title":"Plasmacytoid dendritic cells orchestrate TLR7-mediated innate and adaptive immunity for the initiation of autoimmune inflammation","volume":"6","author":"Takagi","year":"2016","journal-title":"Sci Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0151-1","article-title":"DNA sensing by the cGAS\u2013STING pathway in health and disease","volume":"20","author":"Motwani","year":"2019","journal-title":"Nat Rev Genet"},{"key":"B41","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.immuni.2017.07.016","article-title":"Dendritic Cells but Not Macrophages Sense Tumor Mitochondrial DNA for Cross-priming through Signal Regulatory Protein \u03b1 Signaling","volume":"47","author":"Xu","year":"2017","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.02.036","article-title":"Synergistic STING activation by PC7A nanovaccine and ionizing radiation improves cancer immunotherapy","volume":"300","author":"Luo","year":"2019","journal-title":"J Controlled Release Off J Controlled Release Soc"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.celrep.2019.09.065","article-title":"Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity","volume":"29","author":"Schadt","year":"2019","journal-title":"Cell Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw6421","article-title":"BAF restricts cGAS on nuclear DNA to prevent innate immune activation","volume":"369","author":"Guey","year":"2020","journal-title":"Science"},{"key":"B47","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41586-020-2625-x","article-title":"C9orf72 in myeloid cells suppresses STING-induced inflammation","volume":"585","author":"McCauley","year":"2020","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature25432","article-title":"Chromosomal instability drives metastasis through a cytosolic DNA response","volume":"553","author":"Bakhoum","year":"2018","journal-title":"Nature"},{"key":"B49","doi-asserted-by":"publisher","first-page":"13324","DOI":"10.1038\/ncomms13324","article-title":"Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation","volume":"7","author":"den Brok","year":"2016","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e000649","DOI":"10.1136\/jitc-2020-000649","article-title":"Tumor ablation plus co-administration of CpG and saponin adjuvants affects IL-1 production and multifunctional T cell numbers in tumor draining lymph nodes","volume":"8","author":"Raaijmakers","year":"2020","journal-title":"J ImmunoTher Cancer"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01887","article-title":"Monocyte-Derived Dendritic Cells Dictate the Memory Differentiation of CD8+ T Cells During Acute Infection","volume":"10","author":"Shin","year":"2019","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1126\/science.1151869","article-title":"Dendritic cell-induced memory T cell activation in nonlymphoid tissues","volume":"319","author":"Wakim","year":"2008","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 Agonist Antibodies in Cancer Immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/31002","article-title":"Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions","volume":"393","author":"Schoenberger","year":"1998","journal-title":"Nature"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0253","article-title":"Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells","volume":"4","author":"Dovedi","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02030","article-title":"Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer","volume":"9","author":"Yasmin-Karim","year":"2018","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3821","article-title":"Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer","volume":"78","author":"Rech","year":"2018","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2007.01.018","article-title":"Early activation markers of human peripheral dendritic cells","volume":"68","author":"Hellman","year":"2007","journal-title":"Hum Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(2001010)31:10<3026::aid-immu3026>3.0.co;2-h","article-title":"Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12","volume":"31","author":"Krug","year":"2001","journal-title":"Eur J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031591","article-title":"and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN","volume":"199","author":"Ahonen","year":"2004","journal-title":"J Exp Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.3.1564","article-title":"Combined TLR\/CD40 Stimulation Mediates Potent Cellular Immunity by Regulating Dendritic Cell Expression of CD70 In Vivo","volume":"178","author":"Sanchez","year":"2007","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.4.2160","article-title":"Engagement of the OX-40 receptor in vivo enhances antitumor immunity","volume":"164","author":"Weinberg","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20071341","article-title":"OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection","volume":"205","author":"Piconese","year":"2008","journal-title":"J Exp Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ee238f","article-title":"Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells","volume":"33","author":"Roberts","year":"2010","journal-title":"J Immunother (Hagerstown Md 1997)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133647","article-title":"Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity","volume":"5","author":"Eskiocak","year":"2020","journal-title":"JCI Insight"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00664.x","article-title":"Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer","volume":"99","author":"Yokouchi","year":"2008","journal-title":"Cancer Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-3279","article-title":"Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model","volume":"24","author":"Niknam","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.1158\/0008-5472.CAN-16-0549","article-title":"Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming","volume":"76","author":"Rodriguez-Ruiz","year":"2016","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-0210","article-title":"Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies","volume":"72","author":"Verbrugge","year":"2012","journal-title":"Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"eaan4488","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous malignancy by local immunotherapy","volume":"10","author":"Sagiv-Barfi","year":"2018","journal-title":"Sci Trans Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.1.309","article-title":"Synergistic Activation of Macrophages via CD40 and TLR9 Results in T Cell Independent Antitumor Effects","volume":"176","author":"Buhtoiarov","year":"2006","journal-title":"J Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2200-6","article-title":"Interactions among myeloid regulatory cells in cancer","volume":"68","author":"Umansky","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.432","article-title":"Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines","volume":"33","author":"Butt","year":"2014","journal-title":"Oncogene"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101324","article-title":"Natural innate and adaptive immunity to cancer","volume":"29","author":"Vesely","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1172\/jci117045","article-title":"Transforming growth factor-beta activation in irradiated murine mammary gland","volume":"93","author":"Barcellos-Hoff","year":"1994","journal-title":"J Clin Invest"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1667\/rr0695.1","article-title":"Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species","volume":"166","author":"Jobling","year":"2006","journal-title":"Radiat Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-3511","article-title":"TGF\u03b2 Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity","volume":"75","author":"Vanpouille-Box","year":"2015","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-17-3112","article-title":"A Novel TGF\u03b2 Trap Blocks Chemotherapeutics-Induced TGF\u03b21 Signaling and Enhances Their Anticancer Activity in Gynecologic Cancers","volume":"24","author":"Zhu","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B80","first-page":"18","article-title":"The role of the TGF-beta family in wound healing, burns and scarring: a review","volume":"2","author":"Penn","year":"2012","journal-title":"Int J Burns Trauma"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-0544","article-title":"TGF\u03b21 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo","volume":"17","author":"Bouquet","year":"2011","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2015.07.009","article-title":"The paradoxical role of IL-10 in immunity and cancer","volume":"367","author":"Mannino","year":"2015","journal-title":"Cancer Lett"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.11.003","article-title":"IL-10 Elicits IFN\u03b3-Dependent Tumor Immune Surveillance","volume":"20","author":"Mumm","year":"2011","journal-title":"Cancer Cell"},{"key":"B84","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.ccell.2019.05.005","article-title":"Targeting Tumors with IL-10 Prevents Dendritic Cell-Mediated CD8+ T Cell Apoptosis","volume":"35","author":"Qiao","year":"2019","journal-title":"Cancer Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental Mechanisms of Immune Checkpoint Blockade Therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discovery"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.629187","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma","volume":"12","author":"Wang","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603341","article-title":"Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity","volume":"95","author":"den Brok","year":"2006","journal-title":"Br J Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1782","article-title":"Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy","volume":"72","author":"Waitz","year":"2012","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-020-02505-6","article-title":"CTLA-4 Blockade Suppresses Progression of Residual Tumors and Improves Survival After Insufficient Radiofrequency Ablation in a Subcutaneous Murine Hepatoma Model","volume":"43","author":"Zhang","year":"2020","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0190","article-title":"A Pilot Study of Preoperative Single-Dose Ipilimumab and\/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling","volume":"22","author":"McArthur","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000826","article-title":"Combination of radiotherapy and suppression of Tregs enhances abscopal antitumor effect and inhibits metastasis in rectal cancer","volume":"8","author":"Ji","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz036","article-title":"STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer","volume":"111","author":"Oweida","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1604","article-title":"High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy","volume":"26","author":"Eranki","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1352","article-title":"PD-1 Blockade Boosts Radiofrequency Ablation-Elicited Adaptive Immune Responses against Tumor","volume":"22","author":"Shi","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","first-page":"5421","DOI":"10.1038\/s41467-019-13204-3","article-title":"Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy","volume":"10","author":"Shi","year":"2019","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B101","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1667\/RR13740.1","article-title":"Radiation biology in the context of changing patterns of radiotherapy","volume":"182","author":"Murray","year":"2014","journal-title":"Radiat Res"},{"key":"B104","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.02.001","article-title":"Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment","volume":"41","author":"van de Wall","year":"2020","journal-title":"Trends Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3376","article-title":"Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell-Mediated Tumor Immunity","volume":"78","author":"Bull","year":"2018","journal-title":"Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2017.12.005","article-title":"SIRPalpha-CD47 Immune Checkpoint Blockade in Anticancer Therapy","volume":"39","author":"Veillette","year":"2018","journal-title":"Trends Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell-mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0037-T","article-title":"CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy","volume":"74","author":"Soto-Pantoja","year":"2014","journal-title":"Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.03.001","article-title":"A tetravalent single chain diabody (CD40\/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions","volume":"109","author":"Lu","year":"2019","journal-title":"Mol Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-18-0805","article-title":"A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity","volume":"7","author":"Ye","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-19-0798","article-title":"CD137\/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement","volume":"8","author":"Gaspar","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40425-019-0570-8","article-title":"The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation","volume":"7","author":"Kvarnhammar","year":"2019","journal-title":"J\u00a0ImmunoTher Cancer"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e1648171","DOI":"10.1080\/2162402X.2019.1648171","article-title":"Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy","volume":"8","author":"Mittal","year":"2019","journal-title":"Oncoimmunology"},{"key":"B117","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1158\/1538-7445.AM2016-3217","article-title":"MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART\u00ae) protein with T-cell immunomodulatory activity for cancer treatment","volume":"76","author":"LaMotte-Mohs","year":"2016","journal-title":"Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3548","article-title":"FS118, a Bispecific Antibody Targeting LAG-3 and PD-L1, Enhances T-Cell Activation Resulting in Potent Antitumor Activity","volume":"26","author":"Kraman","year":"2020","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2016.11.006","article-title":"Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies","volume":"25","author":"Dheilly","year":"2017","journal-title":"Mol Ther"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2503","article-title":"SIRPalpha-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells","volume":"22","author":"Piccione","year":"2016","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14500","article-title":"SIRPalpha-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells","volume":"8","author":"Ponce","year":"2017","journal-title":"Oncotarget"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0622-x","article-title":"Targeted glycan degradation potentiates the anticancer immune response in vivo","volume":"16","author":"Gray","year":"2020","journal-title":"Nat Chem Biol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1813-x","article-title":"Systemic delivery of chTNT-3\/CpG immunoconjugates for immunotherapy in murine solid tumor models","volume":"65","author":"Jang","year":"2016","journal-title":"Cancer Immunol Immunother CII"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v99.5.1676","article-title":"In vivo manipulation of dendritic cells to induce therapeutic immunity","volume":"99","author":"Merad","year":"2002","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.1.566","article-title":"Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo","volume":"165","author":"Pulendran","year":"2000","journal-title":"J Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.012","article-title":"Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated","volume":"58","author":"Demaria","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.165.9.5112","article-title":"Recombinant anti-human HER2\/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity","volume":"165","author":"Dela Cruz","year":"2000","journal-title":"J Immunol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12967-015-0397-0","article-title":"NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy","volume":"13","author":"van den Heuvel","year":"2015","journal-title":"J Transl Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0110","article-title":"Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma","volume":"15","author":"Johnson","year":"2009","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2676","article-title":"Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects","volume":"21","author":"Zegers","year":"2015","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e1414119","DOI":"10.1080\/2162402X.2017.1414119","article-title":"The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses","volume":"7","author":"Rekers","year":"2018","journal-title":"Oncoimmunology"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-2644","article-title":"In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments","volume":"76","author":"Morris","year":"2016","journal-title":"Cancer Res"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0353","article-title":"Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites","volume":"6","author":"Morris","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B134","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s40425-019-0823-6","article-title":"Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition","volume":"7","author":"Voeller","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0798","article-title":"Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children\u2019s Oncology Group Phase II Study","volume":"25","author":"Shusterman","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1471-2407-13-20","article-title":"A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors","volume":"13","author":"Connor","year":"2013","journal-title":"BMC Cancer"},{"key":"B137","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-020-07055-1","article-title":"Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial","volume":"20","author":"Lieverse","year":"2020","journal-title":"BMC Cancer"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1863-0","article-title":"Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models","volume":"65","author":"Eckert","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget"},{"key":"B140","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ccr.2013.12.004","article-title":"Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses","volume":"25","author":"Yang","year":"2014","journal-title":"Cancer Cell"},{"key":"B141","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFNalpha to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Nat Commun"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-beta","volume":"10","author":"Lan","year":"2018","journal-title":"Sci Transl Med"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFbeta, in Advanced Solid Tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.617365\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T02:16:12Z","timestamp":1671848172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.617365\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":143,"alternative-id":["10.3389\/fimmu.2021.617365"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.617365","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"article-number":"617365"}}